{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:44:57Z","timestamp":1790999097363,"version":"4.1.0"},"reference-count":122,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2023A1515012905"],"award-info":[{"award-number":["2023A1515012905"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chronic liver diseases (CLDs) cover a spectrum of liver diseases, ranging from nonalcoholic fatty liver disease to liver cancer, representing a growing epidemic worldwide with high unmet medical needs. Glycolysis is a conservative and rigorous process that converts glucose into pyruvate and sustains cells with the energy and intermediate products required for diverse biological activities. However, abnormalities in glycolytic flux during CLD development accelerate the disease progression. Aerobic glycolysis is a hallmark of liver cancer and is responsible for a broad range of oncogenic functions including proliferation, invasion, metastasis, angiogenesis, immune escape, and drug resistance. Recently, the non-neoplastic role of aerobic glycolysis in immune activation and inflammatory disorders, especially CLD, has attracted increasing attention. Several key mediators of aerobic glycolysis, including HIF-1\u03b1 and pyruvate kinase M2 (PKM2), are upregulated during steatohepatitis and liver fibrosis. The pharmacological inhibition or ablation of PKM2 effectively attenuates hepatic inflammation and CLD progression. In this review, we particularly focused on the glycolytic and non-glycolytic roles of PKM2 in the progression of CLD, highlighting the translational potential of a glycolysis-centric therapeutic approach in combating CLD.<\/jats:p>","DOI":"10.3390\/cells12151930","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T01:03:25Z","timestamp":1690333405000},"page":"1930","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Glycolysis in Chronic Liver Diseases: Mechanistic Insights and Therapeutic Opportunities"],"prefix":"10.3390","volume":"12","author":[{"given":"Hengdong","family":"Qu","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, School of Medicine, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: Unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/emm.2015.122","article-title":"Regulation of glucose metabolism from a liver-centric perspective","volume":"48","author":"Han","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrendo.2017.80","article-title":"Regulation of hepatic glucose metabolism in health and disease","volume":"13","author":"Petersen","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","article-title":"Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma","volume":"39","author":"Feng","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/j.gastro.2012.09.008","article-title":"Sterile inflammation in the liver","volume":"143","author":"Kubes","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.smim.2015.09.001","article-title":"Contribution of metabolic reprogramming to macrophage plasticity and function","volume":"27","author":"Stenmark","year":"2015","journal-title":"Semin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.3748\/wjg.v22.i45.9933","article-title":"Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects","volume":"22","author":"Shang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-nutr-062220-105200","article-title":"Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis","volume":"42","author":"Rui","year":"2022","journal-title":"Annu. Rev. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2019.11.029","article-title":"Mitochondrial metabolic reprogramming: An important player in liver cancer progression","volume":"470","author":"Jin","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Delgado, M.E., C\u00e1rdenas, B.I., Farran, N., and Fernandez, M. (2021). Metabolic Reprogramming of Liver Fibrosis. Cells, 10.","DOI":"10.3390\/cells10123604"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.freeradbiomed.2019.08.007","article-title":"Pyruvate kinase M2: A simple molecule with complex functions","volume":"143","author":"Alquraishi","year":"2019","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13578-019-0317-8","article-title":"PKM2, function and expression and regulation","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell. Biosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2014.01.031","article-title":"PKM2 contributes to cancer metabolism","volume":"356","author":"Wong","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ncb2629","article-title":"ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect","volume":"14","author":"Yang","year":"2012","journal-title":"Nat. Cell. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cmet.2014.12.005","article-title":"Pyruvate kinase M2 regulates Hif-1\u03b1 activity and IL-1\u03b2 induction and is a critical determinant of the warburg effect in LPS-activated macrophages","volume":"21","author":"Curtis","year":"2015","journal-title":"Cell Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.15252\/embr.201643300","article-title":"PKM2, cancer metabolism, and the road ahead","volume":"17","author":"Dayton","year":"2016","journal-title":"EMBO Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2020.11.018","article-title":"Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics","volume":"503","author":"Zhu","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"936967","DOI":"10.3389\/fimmu.2022.936967","article-title":"Research progress on the role of PKM2 in the immune response","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10565-021-09605-0","article-title":"Pyruvate kinase M2 in chronic inflammations: A potpourri of crucial protein-protein interactions","volume":"37","author":"Patel","year":"2021","journal-title":"Cell. Biol. Toxicol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"G387","DOI":"10.1152\/ajpgi.00054.2019","article-title":"Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation","volume":"317","author":"Zhao","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"38105","DOI":"10.18632\/oncotarget.9460","article-title":"Phage display library selection of a hypoxia-binding scFv antibody for liver cancer metabolic marker discovery","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.18632\/oncotarget.278","article-title":"No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis","volume":"2","author":"Bluemlein","year":"2011","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.molcel.2020.05.004","article-title":"Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment","volume":"78","author":"Hou","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"589997","DOI":"10.3389\/fimmu.2020.589997","article-title":"PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment","volume":"11","author":"Li","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lv, W.W., Liu, D., Liu, X.C., Feng, T.N., Li, L., Qian, B.Y., and Li, W.X. (2018). Effects of PKM2 on global metabolic changes and prognosis in hepatocellular carcinoma: From gene expression to drug discovery. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5023-0"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12253-019-00630-3","article-title":"Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma","volume":"26","author":"Zhao","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_31","first-page":"2538","article-title":"Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"22193","DOI":"10.18632\/oncotarget.7923","article-title":"SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma","volume":"7","author":"Tai","year":"2016","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v25.i13.1550","article-title":"Hepatocellular carcinoma surveillance: An evidence-based approach","volume":"25","author":"Harris","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fcell.2018.00138","article-title":"High Expression of Glycolytic Genes in Cirrhosis Correlates With the Risk of Developing Liver Cancer","volume":"6","author":"Lee","year":"2018","journal-title":"Front. Cell. Dev. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15294","DOI":"10.1038\/s41598-017-14813-y","article-title":"Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","article-title":"Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade","volume":"68","author":"Zhu","year":"2019","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1136\/gutjnl-2021-326350","article-title":"PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma","volume":"71","author":"Lu","year":"2022","journal-title":"Gut"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-015-0462-6","article-title":"PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma","volume":"14","author":"Yu","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17430","DOI":"10.18632\/oncotarget.24732","article-title":"Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis","volume":"9","author":"Cuenco","year":"2018","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Inomata, Y., Oh, J.W., Taniguchi, K., Sugito, N., Kawaguchi, N., Hirokawa, F., Lee, S.W., Akao, Y., Takai, S., and Kim, K.P. (2022). Downregulation of miR-122-5p Activates Glycolysis via PKM2 in Kupffer Cells of Rat and Mouse Models of Non-Alcoholic Steatohepatitis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095230"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cmet.2021.04.018","article-title":"PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease","volume":"33","author":"Giles","year":"2021","journal-title":"Cell. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.ajpath.2020.08.002","article-title":"Pyruvate Kinase M2 Tetramerization Protects against Hepatic Stellate Cell Activation and Liver Fibrosis","volume":"190","author":"Zheng","year":"2020","journal-title":"Am. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E613","DOI":"10.1152\/ajpendo.00296.2017","article-title":"Nonalcoholic fatty liver disease and gastric bypass surgery regulate serum and hepatic levels of pyruvate kinase isoenzyme M2","volume":"315","author":"Meoli","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic Steatohepatitis: A Review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","article-title":"Non-invasive diagnosis of liver fibrosis and cirrhosis","volume":"21","author":"Lurie","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41568-021-00383-9","article-title":"The immunological and metabolic landscape in primary and metastatic liver cancer","volume":"21","author":"Li","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.32447","article-title":"Emerging immunotherapy for HCC: A guide for hepatologists","volume":"75","author":"Foerster","year":"2022","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-017-0748-y","article-title":"HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma","volume":"16","author":"Xu","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30671","article-title":"Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p\/PKM2 Axis Under Hypoxic Stress","volume":"70","author":"Li","year":"2019","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41467-020-14437-3","article-title":"MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"113514","DOI":"10.1016\/j.yexcr.2023.113514","article-title":"LINC00365 functions as a tumor suppressor by inhibiting HIF-1\u03b1-mediated glucose metabolism reprogramming in breast cancer","volume":"425","author":"Liu","year":"2023","journal-title":"Exp. Cell. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/cac2.12158","article-title":"The role of the HIF-1\u03b1\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13046-018-0892-2","article-title":"Yes-associated protein (YAP) binds to HIF-1\u03b1 and sustains HIF-1\u03b1 protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress","volume":"37","author":"Zhang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","article-title":"Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1","volume":"145","author":"Luo","year":"2011","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cmet.2022.02.013","article-title":"Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer\u2019s disease","volume":"34","author":"Pan","year":"2022","journal-title":"Cell. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"118796","DOI":"10.1016\/j.lfs.2020.118796","article-title":"Shikonin differentially regulates glucose metabolism via PKM2 and HIF1\u03b1 to overcome apoptosis in a refractory HCC cell line","volume":"265","author":"Yang","year":"2021","journal-title":"Life Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13046-020-1528-x","article-title":"Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1\u03b1\/PPAR-\u03b3\/PKM2-mediated glycolysis","volume":"39","author":"Feng","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/hep.30923","article-title":"CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation","volume":"71","author":"Wong","year":"2020","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"102458","DOI":"10.1016\/j.redox.2022.102458","article-title":"GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism","volume":"56","author":"Zhou","year":"2022","journal-title":"Redox Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/path.5856","article-title":"MyD88 in myofibroblasts regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation","volume":"256","author":"Yuan","year":"2022","journal-title":"J. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s11010-020-04041-w","article-title":"PKM2 promotes cell metastasis and inhibits autophagy via the JAK\/STAT3 pathway in hepatocellular carcinoma","volume":"476","author":"Yu","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"846","DOI":"10.18632\/oncotarget.2749","article-title":"PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1085-0","article-title":"The significance of exosomes in the development and treatment of hepatocellular carcinoma","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1101\/gad.278549.116","article-title":"Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma","volume":"30","author":"Dayton","year":"2016","journal-title":"Genes. Dev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-019-0332-8","article-title":"Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis","volume":"17","author":"Zhang","year":"2019","journal-title":"Cell. Commun. Signal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/tox.23346","article-title":"Long noncoding RNA FAM66C promotes tumor progression and glycolysis in intrahepatic cholangiocarcinoma by regulating hsa-miR-23b-3p\/KCND2 axis","volume":"36","author":"Lei","year":"2021","journal-title":"Environ. Toxicol."},{"key":"ref_71","first-page":"298","article-title":"Leptin stimulates the epithelial-mesenchymal transition and pro-angiogenic capability of cholangiocarcinoma cells through the miR-122\/PKM2 axis","volume":"55","author":"Peng","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.31561","article-title":"DNA Methylation of Cannabinoid Receptor Interacting Protein 1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent Pyruvate Kinase M2 Ubiquitination","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver--from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","article-title":"Lipid alterations in chronic liver disease and liver cancer","volume":"4","author":"Paul","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2022.02.031","article-title":"Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis","volume":"77","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2337\/db18-0035","article-title":"HSPA12A Is a Novel Player in Nonalcoholic Steatohepatitis via Promoting Nuclear PKM2-Mediated M1 Macrophage Polarization","volume":"68","author":"Kong","year":"2019","journal-title":"Diabetes"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.omtn.2021.12.017","article-title":"DRAM1 increases the secretion of PKM2-enriched EVs from hepatocytes to promote macrophage activation and disease progression in ALD","volume":"27","author":"Tan","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1136\/gutjnl-2021-325150","article-title":"FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2","volume":"71","author":"Rao","year":"2022","journal-title":"Gut"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1096\/fj.201802675R","article-title":"Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2: A role for exosomes in metabolic switch of liver nonparenchymal cells","volume":"33","author":"Wan","year":"2019","journal-title":"FASEB J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/onc.2011.137","article-title":"Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2","volume":"30","author":"Chen","year":"2011","journal-title":"Oncogene"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nchembio.1060","article-title":"Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis","volume":"8","author":"Anastasiou","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"926945","DOI":"10.3389\/fphar.2022.926945","article-title":"Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_85","first-page":"3575","article-title":"Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma","volume":"11","author":"Lu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2019.10.015","article-title":"Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4(+) T Cell Pathogenicity and Suppresses Autoimmunity","volume":"31","author":"Angiari","year":"2020","journal-title":"Cell. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"174844","DOI":"10.1016\/j.ejphar.2022.174844","article-title":"Inhibition of abnormally activated HIF-1\u03b1-GLUT1\/3-glycolysis pathway enhances the sensitivity of hepatocellular carcinoma to 5-caffeoylquinic acid and its derivatives","volume":"920","author":"Pang","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"11697","DOI":"10.2147\/OTT.S240535","article-title":"Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects Against Hepatocellular Carcinoma Cells","volume":"13","author":"Zeng","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.1080\/21655979.2022.2052673","article-title":"Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells","volume":"13","author":"Zhang","year":"2022","journal-title":"Bioengineered"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.21873\/anticanres.14515","article-title":"Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines","volume":"40","author":"Thonsri","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1159\/000478758","article-title":"TRAIL Enhances Shikonin Induced Apoptosis through ROS\/JNK Signaling in Cholangiocarcinoma Cells","volume":"42","author":"Zhou","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Gwon, S.Y., Ahn, J., Jung, C.H., Moon, B., and Ha, T.Y. (2020). Shikonin Attenuates Hepatic Steatosis by Enhancing Beta Oxidation and Energy Expenditure via AMPK Activation. Nutrients, 12.","DOI":"10.3390\/nu12041133"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jgh.14299","article-title":"Alleviation of hepatic fibrosis and autophagy via inhibition of transforming growth factor-\u03b21\/Smads pathway through shikonin","volume":"34","author":"Liu","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.7150\/thno.60385","article-title":"Pyruvate kinase M2 regulates fibrosis development and progression by controlling glycine auxotrophy in myofibroblasts","volume":"11","author":"Satyanarayana","year":"2021","journal-title":"Theranostics"},{"key":"ref_95","first-page":"4017","article-title":"The PKM2 activator TEPP-46 attenuates MCD feeding-induced nonalcoholic steatohepatitis by inhibiting the activation of Kupffer cells","volume":"25","author":"Yang","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cmet.2018.01.007","article-title":"Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1\u03b1 Transactivation in Steatohepatitis","volume":"27","author":"Ouyang","year":"2018","journal-title":"Cell. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.taap.2019.01.004","article-title":"Metformin delays AKT\/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation","volume":"365","author":"Zhang","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/JHC.S237614","article-title":"Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2","volume":"7","author":"Liu","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1139\/bcb-2018-0310","article-title":"Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1\u03b1 signaling pathway","volume":"97","author":"Liu","year":"2019","journal-title":"Biochem. Cell Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.02.010","article-title":"Transarterial chemoembolization: Modalities, indication, and patient selection","volume":"62","author":"Sieghart","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13046-020-01605-y","article-title":"PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma","volume":"39","author":"Martin","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Li, Z., Zheng, W., Li, H., Li, C., and Gong, Z. (2015). Synergistic Induction of Potential Warburg Effect in Zebrafish Hepatocellular Carcinoma by Co-Transgenic Expression of Myc and xmrk Oncogenes. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132319"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"B080","DOI":"10.1158\/1535-7163.TARG-19-B080","article-title":"Abstract B080: PKM2 activation modulates metabolism and enhances immune response in solid tumor models","volume":"18","author":"Pathi","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.biopha.2018.07.071","article-title":"Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p\/PKM2 axis","volume":"107","author":"Xu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/0008-5472.CAN-20-0948","article-title":"ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth","volume":"82","author":"Ma","year":"2022","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"120133","DOI":"10.1098\/rsob.120133","article-title":"Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides","volume":"2","author":"Wang","year":"2012","journal-title":"Open. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/cr.2016.159","article-title":"Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2","volume":"27","author":"Liang","year":"2017","journal-title":"Cell Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"101634","DOI":"10.1016\/j.redox.2020.101634","article-title":"Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH","volume":"36","author":"Xu","year":"2020","journal-title":"Redox Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.7150\/ijbs.73890","article-title":"Covalent Inhibition of Pyruvate Kinase M2 Reprograms Metabolic and Inflammatory Pathways in Hepatic Macrophages against Non-alcoholic Fatty Liver Disease","volume":"18","author":"Fan","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"110380","DOI":"10.1016\/j.intimp.2023.110380","article-title":"Lapachol treats non-alcoholic fatty liver disease by modulating the M1 polarization of Kupffer cells via PKM2","volume":"120","author":"Yang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.7150\/thno.56490","article-title":"ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM","volume":"11","author":"Zhou","year":"2021","journal-title":"Theranostics"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00109-019-01786-w","article-title":"Macrophage derived TNF\u03b1 promotes hepatic reprogramming to Warburg-like metabolism","volume":"97","author":"Tarasenko","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2013.05.030","article-title":"The metabolomic window into hepatobiliary disease","volume":"59","author":"Idle","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0039-3402516","article-title":"The Matrisome, Inflammation, and Liver Disease","volume":"40","author":"Dolin","year":"2020","journal-title":"Semin. Liver Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/17474124.2021.1949289","article-title":"Chronic liver disease and oxidative stress\u2014A narrative review","volume":"15","author":"Seen","year":"2021","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/cr.2015.68","article-title":"Metabolic reprogramming in macrophages and dendritic cells in innate immunity","volume":"25","author":"Kelly","year":"2015","journal-title":"Cell Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e005414","DOI":"10.1136\/jitc-2022-005414","article-title":"Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model","volume":"10","author":"Verma","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/psp4.12282","article-title":"Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape","volume":"7","author":"Nijsen","year":"2018","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1038\/s41598-018-20348-7","article-title":"A Mathematical Model for Enzyme Clustering in Glucose Metabolism","volume":"8","author":"Jeon","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Mulukutla, B.C., Yongky, A., Daoutidis, P., and Hu, W.S. (2014). Bistability in glycolysis pathway as a physiological switch in energy metabolism. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098756"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Kapuy, O., Makk-Merczel, K., and Szarka, A. (2021). Therapeutic Approach of KRAS Mutant Tumours by the Combination of Pharmacologic Ascorbate and Chloroquine. Biomolecules, 11.","DOI":"10.3390\/biom11050652"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Verma, B.K., Subramaniam, P., and Vadigepalli, R. (2019). Model-based virtual patient analysis of human liver regeneration predicts critical perioperative factors controlling the dynamic mode of response to resection. BMC Syst. Biol., 13.","DOI":"10.1186\/s12918-019-0678-y"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/15\/1930\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:18:59Z","timestamp":1760127539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/15\/1930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":122,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cells12151930"],"URL":"https:\/\/doi.org\/10.3390\/cells12151930","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}